Cytogen Inc (217330) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.059x

Based on the latest financial reports, Cytogen Inc (217330) has a cash flow conversion efficiency ratio of -0.059x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.13 Billion ≈ $-1.44 Million USD) by net assets (₩35.99 Billion ≈ $24.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 217330 equity financing ratio to measure how much of total assets are equity-financed.

Cytogen Inc - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Cytogen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Cytogen Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.

Cytogen Inc Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cytogen Inc ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
ActRO Co. Ltd KQ:290740	-0.024x
Corline Biomedical AB ST:CLBIO	-0.072x
Mereo BioPharma Group PLC ADR NASDAQ:MREO	-0.127x
Analabs Resources Bhd KLSE:7083	-0.013x
Maison Antoine Baud Société Anonyme PA:MLMAB	N/A
Taiwan Alpha Electronic Co Ltd TWO:6204	0.009x
Rotork PLC LSE:ROR	0.070x
Sietel Ltd AU:SSL	-0.001x

Annual Cash Flow Conversion Efficiency for Cytogen Inc (2014–2025)

The table below shows the annual cash flow conversion efficiency of Cytogen Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see 217330 stock market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	₩35.99 Billion ≈ $24.39 Million	₩-6.95 Billion ≈ $-4.71 Million	-0.193x	+1.50%
2024-12-31	₩48.58 Billion ≈ $32.92 Million	₩-9.53 Billion ≈ $-6.46 Million	-0.196x	-37.81%
2023-12-31	₩53.36 Billion ≈ $36.16 Million	₩-7.59 Billion ≈ $-5.15 Million	-0.142x	+87.38%
2022-12-31	₩5.66 Billion ≈ $3.83 Million	₩-6.38 Billion ≈ $-4.32 Million	-1.128x	-396.17%
2021-12-31	₩23.01 Billion ≈ $15.59 Million	₩-5.23 Billion ≈ $-3.54 Million	-0.227x	+6.68%
2020-12-31	₩18.34 Billion ≈ $12.43 Million	₩-4.47 Billion ≈ $-3.03 Million	-0.244x	-29.58%
2019-12-31	₩17.92 Billion ≈ $12.14 Million	₩-3.37 Billion ≈ $-2.28 Million	-0.188x	-49.56%
2018-12-31	₩22.04 Billion ≈ $14.94 Million	₩-2.77 Billion ≈ $-1.88 Million	-0.126x	+72.70%
2017-12-31	₩4.73 Billion ≈ $3.21 Million	₩-2.18 Billion ≈ $-1.48 Million	-0.460x	+90.73%
2016-12-31	₩475.51 Million ≈ $322.25K	₩-2.36 Billion ≈ $-1.60 Million	-4.969x	-551.88%
2015-12-31	₩2.66 Billion ≈ $1.80 Million	₩-2.03 Billion ≈ $-1.37 Million	-0.762x	+64.00%
2014-12-31	₩484.59 Million ≈ $328.40K	₩-1.03 Billion ≈ $-695.41K	-2.118x	--

About Cytogen Inc

KQ:217330 Korea Diagnostics & Research

Market Cap

$48.78 Million

₩71.98 Billion KRW

Market Cap Rank

#21935 Global

#1309 in Korea

Share Price

₩3120.00

Change (1 day)

+1.79%

52-Week Range

₩2320.00 - ₩9420.00

All Time High

₩22599.98